Sector News

What's wrong with the drug pricing climate?

December 6, 2016
Life sciences

Drugmakers haven’t been shy this week about sharing their views on drug pricing and how pharma should proceed in that arena going forward. Thing is, they don’t all agree.

Tensions were on full display Thursday when a panel of biopharma CEOs at the Forbes Healthcare Summit was asked to shed light on why people dislike the industry. The “real reason,” according to Regeneron CEO Len Schleifer? “We as an industry have used price increases to cover up the gaps in innovation,” he said, as quoted by Business Insider. Using acquisitions or price hikes to boost revenue instead of new, innovative products is “not the business I want to be in,” he continued.

Pfizer CEO Ian Read, though, argued that the industry features a variety of different business models—some, for instance, more appropriate for the $38.79 billion Regeneron, and others for $192.23 billion Pfizer. “The total cost of drugs as a percentage of healthcare has not changed in two decades,” he said.

Biopharma’s reputation has taken a beating over the past year and half as politicians, payers and consumers pushed back at the industry’s use of price increases. While a handful of companies—including Turing, Valeant and, most recently, EpiPen-maker Mylan—have taken the brunt of the criticism, the entire industry has felt the heat.

That’s one reason Allergan CEO Brent Saunders has been pushing his peers to limit their price-jacking, as he pledged to do in September with the rollout of his company’s “social contract” with patients. When Allergan’s prices do rise, they’ll do so only once a year, and by a single-digit percentage, the Dublin drugmaker vowed.

Another reason? Saunders would rather see the industry make its own reforms than politicians do it for them. And make no mistake, he warned in a Thursday op-ed—they will.

“Limit your price increases before we all face the impact of government regulation that stifles innovation and patient care,” he wrote.

So far, no one has followed in Allergan’s footsteps when it comes to publishing an official covenant. But that doesn’t mean fellow drugmakers are not watching their every pricing move.

“I’m not saying we’re perfect,” Merck CEO Ken Frazier told Bloomberg Thursday at the Summit. “… But if you look at the whole portfolio, you will see that Merck has tended to be rather restrained when it comes to drug prices,” he noted, calling raising prices without a corresponding benefit “foolhardy.”

The way Mylan CEO Heather Bresch sees it, though, it’ll take more than just corporate restraint to really repair the relationship between pharma and consumers. It’s up to policymakers to increase transparency on how drugs are priced so consumers know where their money’s going, she figures.

“There’s a lack of understanding of where that full list prices goes and how it is divided in the system,” she said at the meeting. “The pharmaceutical pricing system was not built on the idea on consumer engagement.”

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach